erdafitinib (Balversa)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

  • starting dose of 8 mg once daily
  • increase to 9 mg daily if serum phosphate < 5.5 mg/dL, between days 14 & 17.

Tabs: 3 mg, 4 mg, 5 mg

Monitor

Adverse effects

Laboratory

  • FDA-approved companion diagnostic therascreen FGFR RGQ RT-PCR Kit

Mechanism of action

More general terms

References

  1. PubChem: 67462786
  2. Wikipedia: Erdafitinib https://en.wikipedia.org/wiki/Erdafitinib
  3. 3.0 3.1 FDA News Release. April 12, 2019 FDA grants accelerated approval to erdafitinib for metastatic urothelial carcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma

Database